Abstract:Selection of the treatments most likely to combat a patient's tumor is a central aim of precision oncology. We are currently developing a functional precision oncology program at the University of Utah and Huntsman Cancer Institute that combines the multi-omic characterization of a patient's tumor with the functional screening of relevant drug candidates in patient-derived organoid tumor models to identify which drugs are uniquely capable of combating the patient's cancer. Here we present our model-based approach for utilizing the multi-omic tumor data to computationally predict the patient's response to each drug. In this approach, we first identify the genomic and transcriptomic vulnerabilities of the tumor as genes harboring somatic DNA mutations or copy number changes (from paired tumor/normal WGS/WES DNA sequencing data), as well as genes whose expression levels have been significantly altered in the tumor (based on bulk or single-cell RNA sequencing data). Second, using targeting information from drug-gene interaction databases (DGIdb) we compile a list of genes targeted by each drug relevant in the patient's treatment. Third, we utilize gene interaction database knowledge (KEGG) to construct a gene interaction graph to link each drug's gene targets with all of the tumor's vulnerability genes. We then identify all gene interaction paths connecting specific drug target genes with specific vulnerability genes; and score each path and combine all path-specific scores for the target-vulnerability gene pair. Subsequently, we further combine all pairwise scores across all drug target genes and all tumor vulnerability genes and determine the statistical significance of the resulting score by sampling the background distribution of such scores across random drugs, target genes, and vulnerability genes. We have applied our algorithm to predict drug response in advanced breast cancer patients as well as using publicly available tumor cell line data (GDSC2). We have found a high level of concordance between our computational prediction and organoid/cell line screening results, clearly separating sensitive and non-sensitive models. Using Bayesian probability, we compare the drug-specific score distributions of sensitive and non-sensitive models and are able to identify sensitive cell lines/patients with high accuracy. By encapsulating available information on direct gene-gene interactions, the drug's direct gene targets and the collected omic vulnerabilities of the tumor, our model is not only capable of predicting sensitivity to both targeted and chemotherapy agents, but can also provide a mechanistic understanding for the targeting of the tumor. Our approach will be validated and fine-tuned on a large cohort of breast and brain cancer patients as well as patient PDX models, interrogating gene-target interactions to identify novel relevant target genes/pathways. Citation Format: Szabolcs Tarapcsak, Yi Qiao, Xiaomeng Huang, Tony Di Sera, Matthew H. Bailey, Bryan E. Welm, Alana L. Welm, Gabor T. Marth. Model-based cancer therapy selection by linking tumor vulnerabilities to drug mechanism [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl) nr 2723.

Discovery of Therapeutic Agents for Prostate Cancer Using Genome-Scale Metabolic Modeling and Drug Repositioning

Metabolic modeling-based drug repurposing in Glioblastoma

Computational repurposing of oncology drugs through off‐target drug binding interactions from pharmacological databases

Elucidating the Reprograming of Colorectal Cancer Metabolism Using Genome-Scale Metabolic Modeling

Drug Repurposing for Cancer Treatment Through Global Propagation with a Greedy Algorithm in a Multilayer Network

Computational Modeling to Identify Drugs Targeting Metastatic Castration-Resistant Prostate Cancer Characterized by Heightened Glycolysis

Abstract 6205: Identify drugs for metastatic castration-resistance prostate cancer (mCRPC) patients with high glycolytic activity through in silico approach

Versatile Pathway-Centric Approach Based on High-Throughput Sequencing to Anticancer Drug Discovery

Abstract 4673: Genome-scale metabolic models identify gene targets that enhance drug response of drug-resistant breast cancer cells

Integration of a prognostic gene module with a drug sensitivity module to identify drugs that could be repurposed for breast cancer therapy.

In silico exploration of anti-prostate cancer compounds from differential expressed genes

Screening of well-established drugs targeting cancer metabolism: reproducibility of the efficacy of a highly effective drug combination in mice.

Identification of Metabolism-Associated Prostate Cancer Subtypes and Construction of a Prognostic Risk Model

Computational drug discovery pipelines identify NAMPT as a therapeutic target in neuroendocrine prostate cancer

Accurate Drug Repositioning Through Non-tissue-Specific Core Signatures from Cancer Transcriptomes

Abstract 2723: Model-based cancer therapy selection by linking tumor vulnerabilities to drug mechanism

Computational modeling of methionine cycle-based metabolism and DNA methylation and the implications for anti-cancer drug response prediction

High-throughput screening identified selective inhibitors of exosome biogenesis and secretion: A drug repurposing strategy for advanced cancer

Inferring Drug Set and Identifying the Mechanism of Drugs for PC3

Spatial modeling of prostate cancer metabolic gene expression reveals extensive heterogeneity and selective vulnerabilities

Prediction of Synergistic Drug Combinations for Prostate Cancer by Transcriptomic and Network Characteristics